Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications. Debleena Guin et al. Pharmacogenomics J 2023 8

https://phgkb.cdc.gov/PHGKB/specificPHGKB.action?topic=pgx&query=home From the abstract: "A total of 270 articles were retrieved with PGx evidence associated with 19 ASMs including 178 variants across 93 genes, classifying 26 genetic variants as benign/ likely benign, fourteen as drug response markers and three as risk factors for drug response. Only seventeen of these were replicated, with accuracy (up to 95%) in predicting PGx outcomes specific to six ASMs. Eight out of seventeen variants have FDA-approved PGx drug labelling for clinical implementation."